A Pilot, Prospective, Randomized, Double-Blinded, Vehicle- and Comparator-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease
Latest Information Update: 16 Apr 2024
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
Most Recent Events
- 09 Apr 2024 Status changed from active, no longer recruiting to completed.
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 22 Mar 2023 Status changed from recruiting to active, no longer recruiting.